Brief: Transgene, NEC Present First Data On Neoantigen Cancer Vaccine
09/04/2024 17:00
April 9 (Reuters) - Transgene SA TRNG.PA :
* TRANSGENE AND NEC PRESENT FIRST CLINICAL BENEFITS OF
NEOANTIGEN
CANCER VACCINE, TG4050, IN HEAD & NECK CANCER AT AACR 2024
* TRANSGENE AND NEC ARE PREPARING A RANDOMIZED PHASE II
EXTENSION
OF THIS TRIAL SLATED TO START IN Q2 OF 2024
Source text for Eikon: ID:nGNE1vgctC
Further company coverage: TRNG.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs